RxDoctor Payments Data

Donna Eversley, MD

Family Medicine · Glen Burnie, MDNPI 1548245087

Payments from drug & device makers

$5,849in general payments, 2019–2025

Across 325 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$716
  • AbbVie$687
  • Lilly USA, LLC$668
  • Pfizer$565
  • AstraZeneca$294
  • Astellas Pharma US Inc$219
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,841100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,849 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$164,626
Medicare patients
438
Services billed
2,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$103,795
TrulicityDulaglutide72$92,127
JardianceEmpagliflozin68$84,973
EliquisApixaban53$56,133
MounjaroTirzepatide36$41,812
XareltoRivaroxaban15$24,393
EntrestoSacubitril/Valsartan12$21,473
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$17,182
MyrbetriqMirabegron13$13,553
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$12,904
Ezetimibe78$7,756
Atorvastatin Calcium421$6,360
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,317
SymbicortBudesonide/Formoterol Fumarate16$5,378
Metoprolol Succinate207$3,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$668$135,298120 claims
Novo NordiskOzempic$716$103,79591 claims
Boehringer IngelheimJardiance$127$84,97368 claims
PfizerEliquis$565$56,13353 claims
Johnson & JohnsonXarelto$197$24,39315 claims
NovartisEntresto$130$21,47312 claims
AstraZenecaBreztri Aerosphere, Symbicort$294$18,28237 claims
Astellas Pharma US IncMyrbetriq$219$13,55313 claims
AbbVieSynthroid$687$2,74044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →